The FDA partial hold did not allow the trial to finish, the company agreed not to recruit any more patients for the trial and FDA released the hold -- no need for it anymore. The trial was stopped with a reduced sample for the protocol.
NWBO should have reported the reason for the FDA partial hold -- it is clearly material. But they chose to not reveal the reason, only they they had an FDA partial trial hold and then two years later the FDA release. But they had already stopped any additional patients being added to the trial.
Market Data 
Markets 
AI
